Vaxart, Inc.

BMV:VXRT * Stock Report

Market Cap: Mex$2.9b

Vaxart Valuation

Is VXRT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VXRT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VXRT *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VXRT *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VXRT *?

Key metric: As VXRT * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VXRT *. This is calculated by dividing VXRT *'s market cap by their current revenue.
What is VXRT *'s PS Ratio?
PS Ratio8.1x
SalesUS$16.76m
Market CapUS$139.24m

Price to Sales Ratio vs Peers

How does VXRT *'s PS Ratio compare to its peers?

The above table shows the PS ratio for VXRT * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.5x
FENC Fennec Pharmaceuticals
3.4x27.9%US$155.2m
SANN Santhera Pharmaceuticals Holding
0.9x26.8%CHF 101.1m
NANO Nanobiotix
3.5x7.7%€152.6m
CGEN Compugen
2.3x2.3%US$126.2m
VXRT * Vaxart
8.1x45.2%Mex$139.2m

Price-To-Sales vs Peers: VXRT * is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (2.5x).

Price to Sales Ratio vs Industry

How does VXRT *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

275 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies275PS01632486480+
275 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VXRT * is good value based on its Price-To-Sales Ratio (8.1x) compared to the Global Biotechs industry average (9.1x).

Price to Sales Ratio vs Fair Ratio

What is VXRT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VXRT * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VXRT *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VXRT * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$12.00
Mex$97.23
+710.3%
48.0%Mex$160.94Mex$50.29n/a3
Nov ’25n/a
Mex$90.05
0%
48.0%Mex$149.05Mex$46.58n/a3
Oct ’25n/a
Mex$90.05
0%
48.0%Mex$149.05Mex$46.58n/a3
Sep ’25n/a
Mex$90.05
0%
48.0%Mex$149.05Mex$46.58n/a3
Aug ’25n/a
Mex$96.93
0%
52.4%Mex$147.71Mex$46.16n/a2
Jul ’25Mex$13.00
Mex$96.93
+645.6%
52.4%Mex$147.71Mex$46.16n/a2
Jun ’25n/a
Mex$84.22
0%
60.0%Mex$134.75Mex$33.69n/a2
May ’25n/a
Mex$83.55
0%
60.0%Mex$133.68Mex$33.42n/a2
Apr ’25n/a
Mex$83.55
0%
60.0%Mex$133.68Mex$33.42n/a2
Mar ’25Mex$20.50
Mex$86.04
+319.7%
60.0%Mex$137.67Mex$34.42n/a2
Feb ’25Mex$20.00
Mex$86.04
+330.2%
60.0%Mex$137.67Mex$34.42n/a2
Jan ’25n/a
Mex$83.57
0%
68.4%Mex$140.74Mex$26.39n/a2
Dec ’24n/a
Mex$83.57
0%
68.4%Mex$140.74Mex$26.39n/a2
Nov ’24n/a
Mex$79.16
0%
59.5%Mex$140.73Mex$26.39n/a3
Oct ’24n/a
Mex$79.16
0%
59.5%Mex$140.73Mex$26.39n/a3
Sep ’24n/a
Mex$76.68
0%
59.5%Mex$136.32Mex$25.56n/a3
Aug ’24n/a
Mex$100.55
0%
59.5%Mex$172.38Mex$25.86n/a3
Jul ’24n/a
Mex$103.71
0%
59.5%Mex$177.79Mex$26.67Mex$13.003
Jun ’24n/a
Mex$103.71
0%
59.5%Mex$177.79Mex$26.67n/a3
May ’24Mex$12.80
Mex$105.13
+721.3%
59.5%Mex$180.22Mex$27.03n/a3
Apr ’24Mex$13.97
Mex$105.13
+652.5%
59.5%Mex$180.22Mex$27.03n/a3
Mar ’24Mex$15.00
Mex$131.16
+774.4%
47.5%Mex$197.97Mex$29.70Mex$20.504
Feb ’24Mex$20.40
Mex$131.16
+542.9%
47.5%Mex$197.97Mex$29.70Mex$20.004
Jan ’24Mex$15.00
Mex$131.16
+774.4%
47.5%Mex$197.97Mex$29.70n/a4
Dec ’23n/a
Mex$151.77
0%
19.1%Mex$195.83Mex$117.50n/a4
Nov ’23n/a
Mex$156.44
0%
19.1%Mex$201.86Mex$121.12n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a

Incyte

US$13.8b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.

INCY *

US$1,486.00

7D

0%

1Y

n/a